Huntington’s Disease (HD) is a debilitating neurodegenerative disease marked by progressive loss of motor control and cognitive function. Presently, there are no disease-modifying therapies. A potential avenue for slowing or stopping HD progression is to target huntingtin (HTT), or polyglutamine-expanded mutant HTT (mHTT), for degradation using proteasome targeting chimera (PROTAC) technology. A PROTAC will bring […]
Read More